Transplantation of Mitral Allograft into the Tricuspid Position - a Sheep Experimental Model

Autor: Jaroslav Hlubocký, J. Špatenka, J. Vojáček, Mokrácek A, Vlasta Kroupová, Vambera M, J. Kursa, Jan Burkert, Sulda M, P. Kobylka

Publikováno v: Acta Veterinaria Brno, Vol 77, Iss 1, Pp 89-95 (2008)

Our research was focused on finding the optimal technique of cryopreserved mitral allograft implantation into the tricuspid valve position in a sheep experiment. We prepared 20 cryopreserved mitral valve allografts preoperatively. These were implante

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c32418fdc4717f474dd97dce88967e1
https://actavet.vfu.cz/77/1/0089/

[Aortic allograft (homograft) for the treatment of valvular disorders in adults with focus on treatment of infective aortic valve endocarditis]

Autor: Mokrácek A, Jaroslav SPATENKA, Sulda M, Tousek F, Pospísilová H, Vambera M, Setina M, Pesl L

Publikováno v: Europe PubMed Central

Still after 40 years of heart valve prostheses intensive development ideal valve substitute still does not exist. Aortic allograft represents one alternative which could be used for aortic and/or pulmonary valve replacement. This type of biological h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e464ce5a43d8bf20e570137f4a5a6ac9
https://pubmed.ncbi.nlm.nih.gov/17472016

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.

Autor: Lai TH; Division of Hematology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio., Ewald B; Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas., Zecevic A; Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas., Liu C; Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas., Sulda M; Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas., Papaioannou D; Division of Hematology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio., Garzon R; Division of Hematology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio., Blachly JS; Division of Hematology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio., Plunkett W; Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas. deepa.sampath@osumc.edu wplunket@mdanderson.org., Sampath D; Division of Hematology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. deepa.sampath@osumc.edu wplunket@mdanderson.org.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Jul 15; Vol. 22 (14), pp. 3537-49. Date of Electronic Publication: 2016 Feb 08.